The Patent Finder

Fujifilm Cellular Dynamics, Inc.

54 patents currently held · Updated Nov 22, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Cellular Dynamics International, Inc. (to 2018)

12
Ending by 2030
Jun 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 15, 2027
    The maintenance fee for Neural networks formed from cells derived from pluripotent stem cells (US 10,444,227) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
  • 2 fees due May 3 to 10, 2027 · next May 3
  • 1 fee due Aug 16, 2027
    The maintenance fee for Hepatocyte production by forward programming (US 9,260,722) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
  • 3 fees due Sep 17 to 30, 2027 · next Sep 17
  • 1 fee due Nov 3, 2027
    The maintenance fee for Methods for the production of IPS cells using non-viral approach (US 9,328,332) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,644,184Methods for the production of IPS cells using Epstein-Barr (EBV)-based reprogramming vectors
In force
 · USPTO record
In forceUSPTO record
US 9,175,268Methods for the production of iPS cells
In force
 · USPTO record
In forceUSPTO record
US 9,328,332Methods for the production of IPS cells using non-viral approach
In force
 · USPTO record
In forceUSPTO record
US 8,546,140Methods for the production of iPS cells using non-viral approach
In force
 · USPTO record
In forceUSPTO record
US 8,372,642Differentiation of pluripotent cells
In force
 · USPTO record
In forceUSPTO record
US 9,347,044Reprogramming T cells and hematopoietic cells
In force
 · USPTO record
In forceUSPTO record
US 10,221,396Reprogramming T cells and hematopoietic cells
In force
 · USPTO record
In forceUSPTO record
US 8,741,648Reprogramming T cells and hematopoietic cells
In force
 · USPTO record
In forceUSPTO record
US 9,365,827Cardiomyocyte production
In force
 · USPTO record
In forceUSPTO record
US 9,957,482Cardiomyocyte production
In force
 · USPTO record
In forceUSPTO record
10 of 54 patents shown.
Pro members see all 54.
Pro members: see all 54 patents
Also on record, not counted in the 54: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

13 pending · 2 abandoned · 5 no status recorded

Showing 1 to 10 of 20, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/225,894Methods to Prevent Rapid Silencing of Genes in Pluripotent Stem CellsJun 2, 2025Pending
19/214,864May 21, 2025No status recorded
18/886,115Macs-Based Purification of Stem Cell-Derived Retinal Pigment EpitheliumSep 16, 2024Pending
18/824,380Method for Differentiation of Ocular Cells and Use ThereofSep 4, 2024Pending
18/769,320Method for Reproducible Differentiation of Clinical-Grade Retinal Pigment Epithelium CellsJul 10, 2024Pending
18/479,052Apparatus and Methods for Delivery of Cell CompositionsSep 30, 2023Pending
18/449,100Generation of Induced Pluripotent Stem Cells from Small Volumes of Peripheral BloodAug 14, 2023Pending
18/050,963Oct 28, 2022Abandoned
17/931,669Methods for the Production of Committed Cardiac Progenitor CellsSep 13, 2022Pending
17/931,440Compositions of Induced Pluripotent Stem Cell-Derived Cells and Methods of Use ThereofSep 12, 2022Pending
10 of 20 applications shown.
Pro members see all 20 published applications.
Pro members: see all 20 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited